High BRAF mutation frequency does not characterize all melanocytic tumor types

International Journal of Cancer

Volumn 111, Issue 5, 2004, Pages 705-710

  Saldanha, Gerald ^a,c   Purnell, David ^b   Fletcher, Alan ^b   Potter, Linda ^a   Gillies, Angela ^a   Pringle, J Howard ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Blue naevus; BRAF; Melanoma; NRAS; Restriction fragment length polymorphism polymerase chain reaction; Single strand conformation polymorphism; Spitz naevus

Indexed keywords

DNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1;

ARTICLE; BLUE NEVUS; BRAF GENE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; MAJOR CLINICAL STUDY; MELANOCYTE; MELANOMA; NRAS GENE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; SKIN CANCER;

CELL TRANSFORMATION, NEOPLASTIC; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EXONS; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MUTATION; NEVUS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; SKIN NEOPLASMS;

EID: 4043163497     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20325     Document Type: Article

References (14)

1. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
3. Crowson AN, Magro CM, Sanchez-Carpintero I, Mihm MC Jr. The precursors of malignant melanoma. Recent Results Cancer Res 2002;160:75-84.
4. Marks R, Dorevitch AP, Mason G, Greene MH, Clark WH Jr, Tucker MA, Kraemer KH, Elder DE, Fraser MC. Do all melanomas come from "moles"? a study of the histological association between melanocytic naevi and melanoma. Australas J Dermatol 1990;31:77-80.
5. Barnhill RL. Pathology of melanocytic nevi and malignant melanoma. Boston: Butterworth-Heinemann, 1995.
6. Duteille F, Duport G, Larregue M, Neau A, Duriez P, Herve MC. Malignant blue nevus: three new cases and a review of the literature. Ann Plast Surg 1998;41:674-8.
7. Kalakonda N, Rothwell DG, Scarffe JH, Norton JD. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood 2001;98:1555-60.
8. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
9. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
10. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003;63:756-9.
11. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaronson SA. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003;63:3883-5.
12. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003;1653:25-40.
13. Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol 2000;157:967-72.
14. Troxel DB, Sabella JD. Problem areas in pathology practice uncovered by a review of malpractice claims. Am J Surg Pathol 1994;18:821-31.